ORIGINAL ARTICLE

The development of preparations for specific prevention and treatment of anaerobic enterotoxemia and escherichiosis in calves

Gennadiy N. Spiridonov et al. , Andrey I. Nikitin, Haris N. Makaev, Konstantin Kh. Papunidi, Albert N. Chernov, Gulnara H. Murtazina, Anton G. Spiridonov

Gennadiy N. Spiridonov et al.
Biological Safety Lab, Federal Center of Toxicological, Biological and Radiation Safety, Scientific town-2, Kazan city, 420075, Russia. Email: vnivi@mail.ru

Andrey I. Nikitin
Biological Safety Lab, Federal Center of Toxicological, Biological and Radiation Safety, Scientific town-2, Kazan city, 420075, Russia

Haris N. Makaev
Biological Safety Lab, Federal Center of Toxicological, Biological and Radiation Safety, Scientific town-2, Kazan city, 420075, Russia

Konstantin Kh. Papunidi
Biological Safety Lab, Federal Center of Toxicological, Biological and Radiation Safety, Scientific town-2, Kazan city, 420075, Russia

Albert N. Chernov
Biological Safety Lab, Federal Center of Toxicological, Biological and Radiation Safety, Scientific town-2, Kazan city, 420075, Russia

Gulnara H. Murtazina
Biological Safety Lab, Federal Center of Toxicological, Biological and Radiation Safety, Scientific town-2, Kazan city, 420075, Russia

Anton G. Spiridonov
Biological Safety Lab, Federal Center of Toxicological, Biological and Radiation Safety, Scientific town-2, Kazan city, 420075, Russia
Online First: May 11, 2017 | Cite this Article
Spiridonov et al., G., Nikitin, A., Makaev, H., Papunidi, K., Chernov, A., Murtazina, G., Spiridonov, A. 2017. The development of preparations for specific prevention and treatment of anaerobic enterotoxemia and escherichiosis in calves. Bali Medical Journal 6(2): 363-367. DOI:10.15562/bmj.v6i2.520


The preparations for specific prevention and treatment of combined anaerobic enterotoxemia andescherichiosisin calves have not been developed. Taking it into account, the research on the development of combined vaccine, polyvalent hyperimmune therapeutic and preventive serum against these infections in calves was carried out.

When developing biological preparations, inactivated antigens of Clostridium perfringens of Serotypes A, C, D and Escherichia coli that synthesize adhesive antigens К99, A20were used. Harmlessness, antigenic and immunological activity, the therapeutic effectiveness of the developed biological preparations were determined in experiments in laboratory animals. On the farms with a high incidence of these infections, harmlessness and immunological effectiveness of the vaccine administered into down-calving cows and calves aged 15–18 days and therapeutic and preventive properties of hyperimmune serum in the treatment of calves aged 1–20 days were studied. After administering the vaccine into pregnant cows 50–60 days before calving and newborn calves aged 15–18 days for preventive purposes, the incidence of calves on the farms reduces by 4.6 times, their survival increases by 16.6%. The application of the hyperimmune serum obtained by hyperimmunization of stud bulls with inactivated antigens of C. perfringens and E. coli bacteria for therapeutic purposes allow you to cure 93.0% of calves diseased with anaerobic enterotoxemia and escherichiosis that is 13.6% higher than in the case of treatment of diseased calves with gentamicin and streptomycin. In the group of the calves treated with preventive hyperimmune serum, 29.6% of the animals fell ill, and 5.7% of the animals died, whereas in the control group82.7% of intact calves became ill and 17.3% of diseased calves died. Based on the results of laboratory and on-farm experiments on testing the developed biological preparations, normative documents regulating their production and application were developed and approved by the Scientific Council of the FGBI “Federal Centre for Animal Health” and the Rossel khoznadzor with the aim to implement them in veterinary practice. The novelty of the developed therapeutic and preventive preparations is confirmed by the invention patents of the Russian Federation No. 2428202 and No. 2523389.

No Supplimentary Material available for this article.
Article Views      : 33
PDF Downloads : 16